Last reviewed · How we verify
SAR245409
At a glance
| Generic name | SAR245409 |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen (PHASE1, PHASE2)
- A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma (PHASE1)
- Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer (PHASE2)
- Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer (PHASE1, PHASE2)
- Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia (PHASE1)
- A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia (PHASE2)
- Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAR245409 CI brief — competitive landscape report
- SAR245409 updates RSS · CI watch RSS
- Sanofi portfolio CI